Summary schematic of the main statistically significant results of the effects of the three running modalities on the upper limbs compared with the sedentary group. by Andy Xavier (20141395)

Downregulation of <i>TcPiezo1</i> expression decreases Ca²⁺ entry in <i>T. cruzi.</i> by Guozhong Huang (673424)

“…(B) Downregulation of <i>TcPiezo1</i> expression showed a significant decrease of intracellular Ca²⁺ (+Tet). …”

Characteristics of the participants (mean ± SD): Age and biomarkers. by Chul-young Bae (14709766)

Subjects:

Characteristics of the participants (mean ± SD): Lifestyle (numeric). by Chul-young Bae (14709766)

Subjects:

a.) Mean FB ratios by sample. b) Mean FB ratios by racial group. by Zoë Dinkel (21402766)

Subjects:

AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner. by Matthew Drill (22258391)

“…Cell numbers were significantly decreased in cells after treatment with AZ10606120 (50µM) compared to both temozolomide (TMZ; 50µM) treatment and untreated controls. …”

Statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects: